Nicholas Investment Partners LP Has $5.43 Million Position in Loxo Oncology, Inc. (LOXO)

Nicholas Investment Partners LP lessened its stake in Loxo Oncology, Inc. (NASDAQ:LOXO) by 6.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,921 shares of the biopharmaceutical company’s stock after selling 3,889 shares during the quarter. Nicholas Investment Partners LP owned about 0.20% of Loxo Oncology worth $5,428,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the stock. Legal & General Group Plc raised its stake in Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 284 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in Loxo Oncology by 31.3% in the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 419 shares in the last quarter. Wells Fargo & Company MN raised its stake in Loxo Oncology by 3.8% in the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 592 shares in the last quarter. New York State Common Retirement Fund raised its stake in Loxo Oncology by 2.9% in the third quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock valued at $2,312,000 after purchasing an additional 700 shares in the last quarter. Finally, California State Teachers Retirement System raised its stake in Loxo Oncology by 3.1% in the third quarter. California State Teachers Retirement System now owns 36,594 shares of the biopharmaceutical company’s stock valued at $3,371,000 after purchasing an additional 1,094 shares in the last quarter.

A number of research analysts recently commented on the company. Zacks Investment Research downgraded Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Friday. William Blair assumed coverage on Loxo Oncology in a research note on Tuesday, November 28th. They issued an “outperform” rating for the company. Citigroup dropped their price target on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. JMP Securities upgraded Loxo Oncology from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $77.18 to $95.00 in a research report on Tuesday, November 14th. Finally, Ifs Securities upgraded Loxo Oncology from an “outperform” rating to a “strong-buy” rating in a research report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $90.57.

Loxo Oncology, Inc. (NASDAQ:LOXO) opened at $76.75 on Tuesday. Loxo Oncology, Inc. has a 12-month low of $25.25 and a 12-month high of $95.92.

In other news, Director Avi Z. Naider sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $90.00, for a total transaction of $450,000.00. Following the sale, the director now directly owns 154,118 shares in the company, valued at $13,870,620. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Joshua H. Bilenker sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $74.45, for a total value of $1,116,750.00. Following the sale, the chief executive officer now owns 182,707 shares in the company, valued at $13,602,536.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,123,596 shares of company stock worth $84,872,356. Company insiders own 27.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/12/05/nicholas-investment-partners-lp-has-5-43-million-position-in-loxo-oncology-inc-loxo.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

What are top analysts saying about Loxo Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Loxo Oncology Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit